Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 27, 2012 16:30 ET | Source: Ocera Therapeutics, Inc.

Tranzyme Pharma and Norgine Complete Enrollment in ULISES 008, the Second of Two Phase 3 Pivotal Trials of Ulimorelin

RESEARCH TRIANGLE PARK, N.C. and AMSTERDAM, the Netherlands, Feb. 27, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) and Norgine B.V. today announced completion of patient enrollment in ULISES...
February 21, 2012 05:10 ET | Source: Ocera Therapeutics, Inc.

Tranzyme Pharma to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced that Vipin K. Garg, Ph.D., President and CEO, and Richard I. Eisenstadt, Vice President...
February 14, 2012 05:10 ET | Source: Ocera Therapeutics, Inc.

Tranzyme Pharma to Report Fourth Quarter and Year-End 2011 Financial Results

RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that it will host a conference call on Wednesday, February 29, 2012 at 8:30 am ET to...
February 07, 2012 05:10 ET | Source: Ocera Therapeutics, Inc.

Tranzyme Pharma to Present at BIO CEO & Investor Conference

RESEARCH TRIANGLE PARK, N.C., Feb. 7, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that Vipin K. Garg, Ph.D., President and CEO, will present at the BIO CEO & Investor...
February 01, 2012 16:30 ET | Source: Ocera Therapeutics, Inc.

Tranzyme Pharma Secures Additional $9.3 Million Debt Financing

RESEARCH TRIANGLE PARK, N.C., Feb. 1, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced that it received an additional net $9.3 million in term loan proceeds through an amendment...
December 07, 2011 05:10 ET | Source: Ocera Therapeutics, Inc.

Tranzyme Pharma and Norgine Complete Enrollment in First of Two Pivotal Phase 3 Trials of Ulimorelin

RESEARCH TRIANGLE PARK, N.C., Dec. 7, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) and Norgine B.V. today announced completion of patient enrollment in ULISES 007, the first of two Phase 3...
November 22, 2011 05:10 ET | Source: Ocera Therapeutics, Inc.

Tranzyme Pharma to Present at Piper Jaffray 23rd Annual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 22, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that Vipin Garg, President and CEO, will present at the Piper Jaffray 23rd Annual...
November 10, 2011 16:30 ET | Source: Ocera Therapeutics, Inc.

Tranzyme Pharma Announces Third Quarter 2011 Financial Results

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), a late-stage biopharmaceutical company focused on discovering, developing and commercializing novel,...
November 08, 2011 05:10 ET | Source: Ocera Therapeutics, Inc.

Tranzyme Pharma Announces the Extension of Its Chemistry-Based Drug Discovery Collaboration With Bristol-Myers Squibb

RESEARCH TRIANGLE PARK, N.C., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced the extension of its chemistry-based drug discovery collaboration with Bristol-Myers Squibb...
November 01, 2011 05:10 ET | Source: Ocera Therapeutics, Inc.

Tranzyme Pharma to Report Third Quarter 2011 Financial Results

RESEARCH TRIANGLE PARK, N.C., Nov. 1, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that it will host a conference call on Friday, November 11, 2011 at 8:30 A.M. ET to...